Institution

Why Research Institutions Matter for Deep Tech

The topic may seem rhetorical. We all agree that research institutions matter enormously, especially in deep tech. But their role goes far beyond producing research papers or patents. They are often the foundation on which entire deep-tech ecosystems are built.

Deep-tech companies often require years of scientific and engineering development before a commercially viable product emerges. Much of that foundational work happens long before a startup exists. The laboratory is, in effect, a form of early-stage risk capital for science and technology.

Institution

Research institutions carry the earliest risk.

Research institutions embrace failure as a path to learning and discovery. They can undertake projects that most corporate boards would not approve because outcomes are uncertain, development cycles are long, or the commercial application is not yet obvious. They create an environment where researchers can explore ideas without demonstrating an immediate commercial return.

Institution

Talent, tacit knowledge and infrastructure

Few places provide the concentration of specialised talent that leading research institutions can. Scientists, engineers, students and domain experts work alongside one another, accumulating expertise developed through years of experimentation that cannot easily be documented or replicated. Deep-tech research also requires clean rooms, synchrotrons, testing facilities, high-performance computing and advanced scientific software, tools an early company could not build alone.

Institution

A win-win partnership

Venture capital is designed to generate returns within a finite horizon, while many deep-tech development timelines are longer. The research lab can be the origin of the technology; the venture investor can help build the company around it. The opportunity is not to commercialise every piece of research, but to recognise when a piece has crossed from interesting research to potentially transformative technology.

Institution

India’s landscape

India has no shortage of scientific and engineering talent. IITs, IISc, CSIR laboratories and national research institutions can become engines of deep-tech company creation. But a country of this scale needs more research capacity, specialised infrastructure, capital willing to support long cycles, and stronger bridges between research and commercialisation.

Institution

Building the deep-tech flywheel

Research creates breakthroughs. Breakthroughs create intellectual property. IP attracts capital and creates new startups. Startups create products and industries. Industries fuel new research. Venture capital is integral to that flywheel, but cannot operate in isolation.

Partnership

Research Partnerships in Indian DeepTech

Capital deployment in Indian DeepTech remains challenging, but the difficulty is no longer simply access to deep tech. Nearly 500–600 DeepTech ventures get registered with the country’s 1,100+ incubation centres annually. Cutting through the noise requires a strong thesis and a strong network.

Partnership

Domain expertise

DeepTech can never be amalgamated under one blanket term. Sector-specific programmes create strong early environments for a startup to grow, with continuity in focus areas and ecosystem-building exercises. They help funds refine investment opinions for their respective domains.

Partnership

Opportunity mapping

Research institutions house PhDs and entrepreneurs working on solutions capable of transforming their industries. SilverX collaborates with institutions with procedural knowledge, identifies best-in-class innovation and makes timely introductions selectively. Connections become personal; access to innovation becomes decentralised.

Partnership

Infrastructure

Access to the best labs, government funding options, mentors and research work is of utmost importance. The milestones from research to reality indicate whether a research centre is performing well.

Partnership

Policy, innovation and demand

Incubation and research centres sit between private capital, innovation and government support. Research partnerships with the right stakeholders help us navigate segments and time the market better.

Partnership

Mentorship and think tanks

Partnerships that extend into mentorship for portfolio companies, think tanks and thought leadership help SilverX deal with the uncertainties and opportunities in deeptech investments more proactively.

Partnership

Investor-in-residence

SilverX engages as an investor-in-residence: exploring collaboration beyond sharing investable opportunities, and enabling a stronger ecosystem with several nodes of contribution as both investor and advisor.

Translation

The Translation Problem

A founder walks into a venture meeting and says, “We’re at TRL 5.” The investor writes it down. Neither means the same thing. This is rarely a failure of intelligence. It is a failure of shared units.

Biotech operates across three separate vocabularies: readiness, revenue and probability. Each means something different to founders and investors. That is where deals quietly die.

Translation

The clock problem underneath everything

A venture fund typically has a ten-year life, while clinical-stage drug development can take eight to ten years from first-in-human studies to approval. The honest question is not “When do you generate revenue?” It is “What does the next ₹40 crore prove, and who will pay more for the company once it is proven?”

Translation

Readiness: why TRL breaks in biology

TRL works well for things you can build, test in a controlled environment and test in the field. Biology is different. A readiness claim needs the level, the evidence and the system in which evidence was generated. Readiness moves along three independent axes: biological, manufacturing and regulatory.

Translation

Revenue timelines: replace the curve

For a preclinical biotech, “Revenue starts in FY29” is usually fiction. Replace the revenue curve with a value-inflection curve: an IND-enabling package, a Phase 1 safety read-out, or proof-of-mechanism in patients. State what evidence is produced, what capital is required, and who re-rates the company.

Translation

Probability: stop pretending certainty exists

Published clinical development success rates vary from roughly 7% to 20% depending on the unit and methodology. A credible answer names the base rate and its unit, names the adjusters, gives a range, and names the killer experiment.

Translation

The shared grammar

The solution is not to simplify the science. It is to translate it: evidence before labels, inflections before forecasts, base rates before confidence.